All Stories

  1. Real‐World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)
  2. The Oral Microbiota: Implications in Mucosal Health and Systemic Disease—Crosstalk with Gut and Brain
  3. Evaluation of the Antihistamine and Anti-Inflammatory Effects of a Nutraceutical Blend Based on Quercetin, Perilla frutescens, Boswellia serrata, Blackcurrant, Parthenium, Helichrysum, Lactobacillus acidophilus and Bifidobacterium animalis Through In V...
  4. Dupilumab-Induced Blood Eosinophilia in Patients With Chronic Rhinosinusitis With Nasal Polyps: Temporal Trends and Correlation With Adverse Events
  5. Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)
  6. Two‐Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage
  7. Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience
  8. Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review
  9. Patient-Specific Factors to Differentiate Between Branchial Cleft Cysts and CUP Syndrome: A 10 Year Unicenter Study
  10. Defining two dimensional transthoracic echocardiographic aorta dimension reference ranges in healthy subjects: a machine learning based model
  11. The Emerging Role of MicroRNAs in Nasal Inflammatory Diseases and Tumors: From Bench to Bedside
  12. Pilot Study on the Efficacy of a Novel Questionnaire for Assessing Psychological Health in Patients with Chronic Rhinosinusitis with Nasal Polyps Treated with Biologics
  13. Narrative Review of Genetic and Immunological Mechanisms Involved in the Pathogenesis of Kimura’s Disease: New Therapeutic Targets
  14. Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)
  15. Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics
  16. Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)
  17. Allergic Rhinitis in Professional Singers: A Monoinstitutional Series
  18. Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab
  19. Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study
  20. Kurzfristige Lebensqualitätsbewertung nach Nasennebenhöhlenoperation bei chronischer Rhinosinusitis
  21. Open-door extended endoscopic transorbital technique to the paramedian anterior and middle cranial fossae: technical notes, anatomomorphometric quantitative analysis, and illustrative case
  22. Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era—A 5-Year Follow-Up Study
  23. Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)
  24. Perceptual, aerodynamic and acoustic outcomes of surgical technique for sulcus vocalis patients: A systematic review and meta analysis
  25. TIVA and TCI in Modern Anesthesia
  26. Normative data for interpreting the SNOT-22
  27. The Impact of Antibiotics and Steroids on the Nasal Microbiome in Patients with Chronic Rhinosinusitis: A Systematic Review According to PICO Criteria
  28. Chronic Rhinosinusitis with Nasal Polyps: A Survey on Routine Management and Evaluation of Disease Control in Practice
  29. High-Definition 3D Exoscope in Pediatric Otorhinolaryngology: A Systematic Literature Review
  30. Impatto della pandemia COVID-19 sull’otorinolaringoiatria pediatrica
  31. Raccomandazioni pratiche nella gestione ambulatoriale della rinosinusite cronica con poliposi nasale severa, nell’era dei biologici
  32. Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis
  33. Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
  34. Normative values of the topological metrics of the structural connectome: A multi-site reproducibility study across the Italian Neuroscience network
  35. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)
  36. Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts
  37. Can patient-reported outcomes and inflammatory markers define endotype 2 in chronic rhinosinusitis without nasal polyps?
  38. La gestione del paziente con rinosinusite cronica e poliposi nasale in Italia: expert opinion sul percorso diagnostico-terapeutico
  39. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
  40. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology
  41. Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?
  42. Does a closed reduction improve aesthetical and functional outcome after nasal fracture?
  43. Systematic Review of Parotid Gland Sarcomas: Multi-Variate Analysis of Clinicopathologic Findings, Therapeutic Approaches and Oncological Outcomes That Affect Survival Rate
  44. Effects of the Silica Dust on the Nasal Mucosa of Ceramic Workers
  45. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
  46. The Role of Allergen-Specific Immunotherapy in ENT Diseases: A Systematic Review
  47. Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics
  48. Long-term outcomes and quality of life following parotidectomy for benign disease
  49. Survey on Use of Local and Systemic Corticosteroids in the Management of Chronic Rhinosinusitis with Nasal Polyps: Identification of Unmet Clinical Needs
  50. The Present and Future of Allergen Immunotherapy in Personalized Medicine
  51. Quantitative MRI Harmonization to Maximize Clinical Impact: The RIN–Neuroimaging Network
  52. Advances in chronic rhinosinusitis in 2020 and 2021
  53. Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19
  54. Correlation between olfactory function, age, sex, and cognitive reserve index in the Italian population
  55. Sensitization to Gibberellin-Regulated Protein (Peamaclein) Among Italian Cypress Pollen–Sensitized Patients
  56. Ceramic Workers and the Inflammatory Effects of the Silica Dust on the Nasal Mucosa Detected by Nasal Cytology: a Pilot Study
  57. Perioperative Management of Patients Affected by Ischemic Cardiomyopathy
  58. Allergen Immunotherapy management during vaccinations: An international survey
  59. Bilateral and Ipsilateral Central Neck Dissection in Total Thyroidectomy: a Long Term Comparison of Complications
  60. Nasal cytology identifies allergic rhinitis phenotypes for managing allergen immunotherapy in clinical practice
  61. Diagnostic performance of nasal cytology
  62. How to predict the outcome of septorhinoplasty? A normative study of ROE and FROI-17 scores
  63. Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis
  64. The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
  65. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management
  66. Long-term omalizumab efficacy in allergic rhinitis
  67. Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis
  68. Mepolizumab Effectiveness and Allergic Status in Real Life
  69. Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction
  70. Diagnosis of Obstructive Sleep Apnea in Patients with Allergic and Non-Allergic Rhinitis
  71. The role of allergoids in allergen immunotherapy: from injective to sublingual route
  72. Eosinophilic lingual tonsillitis induced by sublingual immunotherapy: A case series
  73. Role of invariant natural killer t cells in patients with tonsillar hypertrophy: the tonsil as an immunological organ.
  74. Effects of paraprobiotic MIMLh5 in the treatment of chronic rhinopharyngitis
  75. Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications
  76. Biologics for chronic rhinosinusitis with nasal polyps
  77. Total Versus Completion Thyroidectomy: A Multidimensional Evaluation of Long-Term Vocal Alterations
  78. The spectrum of therapeutic activity of mepolizumab
  79. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
  80. Size and shape of the inferior vena cava before and after a fluid challenge: a pilot study
  81. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps
  82. Postoperative Pain Management
  83. Changes of NGF pathway in allergic rhinoconjunctivitis: A conjunctival allergen challenge study
  84. Therapeutic Applications of Capsaicin in Upper Airways
  85. Factors reducing omalizumab response in severe asthma
  86. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma
  87. Atrial Fibrillation in the Perioperative Period
  88. Relationship Between Autism And Nasal Cytology
  89. A survey on features of allergic rhinitis in children
  90. Characteristics of Candidates for Allergen Immunotherapy
  91. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy
  92. maxon motor launches innovative 040 mm,150 watt high power DC motor